印度制药商将三种抗癌药物的价格降低了50%至63%。 - Suppr | 超能文献

Indian drug maker cuts price of three cancer drugs by between 50% and 63%.

作者信息

Kay Meera

出版信息

BMJ. 2012 Nov 16;345:e7786. doi: 10.1136/bmj.e7786.

DOI:10.1136/bmj.e7786

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Indian drug maker cuts price of three cancer drugs by between 50% and 63%.印度制药商将三种抗癌药物的价格降低了50%至63%。

BMJ. 2012 Nov 16;345:e7786. doi: 10.1136/bmj.e7786.

2

Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.对以下内容的评论与回复：从德国医疗保健角度比较厄洛替尼、多西他赛和培美曲塞用于非小细胞肺癌二线治疗的估计成本。

J Med Econ. 2008;11(2):363-66; author reply 366-70. doi: 10.3111/13696990802113147.

3

Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.用于治疗人表皮生长因子受体 2 阳性转移性乳腺癌的口服和静脉用抗癌药物的预算影响分析。

J Med Econ. 2013;16(1):96-107. doi: 10.3111/13696998.2012.729549. Epub 2012 Sep 26.

4

Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.疗效不一定等同于成本效益：一项关于21世纪癌症药物定价相关挑战的案例研究。

J Clin Oncol. 2009 May 1;27(13):2111-3. doi: 10.1200/JCO.2008.21.0534. Epub 2009 Mar 30.

5

Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.口服卡培他滨与静脉紫杉醇类化疗药物一线治疗转移性乳腺癌的成本影响比较。

J Med Econ. 2009 Sep;12(3):238-45. doi: 10.3111/13696990903269673.

6

Financial incentives in cancer care and impact on prescribing practice.癌症治疗中的经济激励措施及其对处方行为的影响。

J Clin Oncol. 2013 Aug 10;31(23):2973-4. doi: 10.1200/JCO.2013.49.5457. Epub 2013 Jul 15.

7

Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.基于卡培他滨的化疗在转移性结直肠癌中的药物经济学效益。

J Clin Oncol. 2008 May 1;26(13):2224-6; author reply 2228. doi: 10.1200/JCO.2008.16.2826.

8

Price, value, and the cost of cancer drugs.癌症药物的价格、价值与成本

Lancet Oncol. 2016 Jan;17(1):3-5. doi: 10.1016/S1470-2045(15)00564-1. Epub 2015 Dec 23.

9

The development of a value based pricing index for new drugs in metastatic colorectal cancer.新型转移性结直肠癌药物基于价值的定价指数的制定。

Eur J Cancer. 2011 Jun;47(9):1299-304. doi: 10.1016/j.ejca.2011.03.015. Epub 2011 Apr 13.

10

XELOX in colorectal cancer: a convenient option for the future?XELOX 在结直肠癌中的应用：未来的便利选择？

Expert Rev Gastroenterol Hepatol. 2011 Feb;5(1):9-19. doi: 10.1586/egh.10.90.